Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost study.

IF 5.7 2区医学 Q1 IMMUNOLOGY Frontiers in Immunology Pub Date : 2025-03-05 eCollection Date: 2025-01-01 DOI:10.3389/fimmu.2025.1550279

Masaya Fujitani, Xiuyuan Lu, Ryo Shinnakasu, Takeshi Inoue, Yujiro Kidani, Naomi M Seki, Satoru Ishida, Shungo Mitsuki, Takeshi Ishihara, Miwa Aoki, Akio Suzuki, Koji Takahashi, Masahiro Takayama, Takeshi Ota, Satoshi Iwata, Risa Yokokawa Shibata, Takuhiro Sonoyama, Mari Ariyasu, Ayumi Kitano, Tommy Terooatea, Jordan Kelly Villa, Kazuo Yamashita, Sho Yamasaki, Tomohiro Kurosaki, Shinya Omoto

{"title":"Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost study.","authors":"Masaya Fujitani, Xiuyuan Lu, Ryo Shinnakasu, Takeshi Inoue, Yujiro Kidani, Naomi M Seki, Satoru Ishida, Shungo Mitsuki, Takeshi Ishihara, Miwa Aoki, Akio Suzuki, Koji Takahashi, Masahiro Takayama, Takeshi Ota, Satoshi Iwata, Risa Yokokawa Shibata, Takuhiro Sonoyama, Mari Ariyasu, Ayumi Kitano, Tommy Terooatea, Jordan Kelly Villa, Kazuo Yamashita, Sho Yamasaki, Tomohiro Kurosaki, Shinya Omoto","doi":"10.3389/fimmu.2025.1550279","DOIUrl":null,"url":null,"abstract":"Background: The durability of vaccine-induced immune memory to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial for preventing infection, especially severe disease.Methods: This follow-up report from a phase 1/2 study of S-268019-b (a recombinant spike protein vaccine) after homologous booster vaccination confirms its long-term safety, tolerability, and immunogenicity.Results: Booster vaccination with S-268019-b resulted in an enhancement of serum neutralizing antibody (NAb) titers and a broad range of viral neutralization. Single-cell immune profiling revealed persistent and mature antigen-specific memory B cells and T follicular helper cells, with increased B-cell receptor diversity. The expansion of B- and T-cell repertoires and presence of cross-reactive NAbs targeting conserved epitopes within the receptor-binding domain following a booster accounted for the broad-spectrum neutralizing activity.Conclusion: These findings highlight the potential of S-268019-b to provide broad and robust protection against a range of SARS-CoV-2 variants, addressing a critical challenge in the ongoing fight against coronavirus disease 2019 (COVID-19).","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1550279"},"PeriodicalIF":5.7000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11919840/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fimmu.2025.1550279","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The durability of vaccine-induced immune memory to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial for preventing infection, especially severe disease.

Methods: This follow-up report from a phase 1/2 study of S-268019-b (a recombinant spike protein vaccine) after homologous booster vaccination confirms its long-term safety, tolerability, and immunogenicity.

Results: Booster vaccination with S-268019-b resulted in an enhancement of serum neutralizing antibody (NAb) titers and a broad range of viral neutralization. Single-cell immune profiling revealed persistent and mature antigen-specific memory B cells and T follicular helper cells, with increased B-cell receptor diversity. The expansion of B- and T-cell repertoires and presence of cross-reactive NAbs targeting conserved epitopes within the receptor-binding domain following a booster accounted for the broad-spectrum neutralizing activity.

Conclusion: These findings highlight the potential of S-268019-b to provide broad and robust protection against a range of SARS-CoV-2 variants, addressing a critical challenge in the ongoing fight against coronavirus disease 2019 (COVID-19).

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Frontiers in Immunology IMMUNOLOGY-

CiteScore

9.80

自引率

11.00%

发文量

7153

审稿时长

14 weeks

期刊介绍： Frontiers in Immunology is a leading journal in its field, publishing rigorously peer-reviewed research across basic, translational and clinical immunology. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. Frontiers in Immunology is the official Journal of the International Union of Immunological Societies (IUIS). Encompassing the entire field of Immunology, this journal welcomes papers that investigate basic mechanisms of immune system development and function, with a particular emphasis given to the description of the clinical and immunological phenotype of human immune disorders, and on the definition of their molecular basis.